It has been demonstrated that some nonmotor symptoms in MDS‐UPDRS I, like cognitive impairment and autonomic dysfunction, can precede dopamine transporter deficit in nonmanifesting LRRK2 mutation carriers.15 This evidence concerns the gene SLC6A3 and Abnormal autonomic nervous system physiology.